Press Release: Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

新聞公告：Entero Therapeutics宣佈擬與Journey Therapeutics進行反向併購，Journey Therapeutics是一家處於臨床階段的，首創類ADC核與納米免疫結合生物製藥公司。

道瓊斯 · 2024/11/13 20:00

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

登入免費觀看全文

登入/註冊

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

Press Release: Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Press Release: Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

風險及免責聲明

聲明